<DOC>
	<DOCNO>NCT00665717</DOCNO>
	<brief_summary>The purpose trial determine effect raltegravir pravastatin pharmacokinetics vice versa intrasubject comparison .</brief_summary>
	<brief_title>The Influence Raltegravir Pravastatin Pharmacokinetics ( GRAPPA )</brief_title>
	<detailed_description>Pravastatin first choice statin HIV-infected patient . Therefore , raltegravir pravastatin expect co-administered frequently HIV-infected patients.Since agent share metabolic pathway , potential pharmacokinetic drug-drug interaction . Because co-administration indicate many HIV-infected patient , essential investigate potential interaction .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Subject least 18 old 55 year age . Subject smoke 10 cigarette , 2 cigar , 2 pipe per day . Subject Quetelet Index ( Body Mass Index ) 18 30 kg/m2 . Subject able willing sign Informed Consent Form prior screen evaluation . Subject good ageappropriate health condition . Subject normal blood pressure pulse rate . Documented history sensitivity/idiosyncrasy medicinal product excipients . Positive HIV test . Positive hepatitis B C test . Pregnant female breastfeed female . Therapy drug . Relevant history presence pulmonary disorder ( especially COPD ) , cardiovascular disorder , neurological disorder ( especially seizures migraine ) , gastrointestinal disorder , renal hepatic disorder , hormonal disorder ( especially diabetes mellitus ) , coagulation disorder . Fasting triglyceride level &gt; 8.0 mmol/L Relevant history current condition might interfere drug absorption , distribution , metabolism excretion . History current abuse drug , alcohol solvent . Inability understand nature extent trial procedure require . Participation drug trial within 60 day prior first dose . Donation blood within 60 day prior first dose . Febrile illness within 3 day first dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>interaction</keyword>
	<keyword>statin</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>